Articles tagged "Hepatocellular carcinoma"

2020 American Transplant Congress
Performance of the Retreat Score in Predicting Post-Transplant Hepatocellular Carcinoma Recurrence at a Large Academic Center
N. Mahmud, N. Philips, S. Ekpanyapong, S. Prenner, M. Levine, R. Reddy, M. Hoteit
Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: Post-transplant hepatocellular carcinoma recurrence (R-HCC) results in poor outcomes. The RETREAT score was recently derived to predict HCC recurrence, incorporating pre-transplant alpha fetoprotein and…
2020 American Transplant Congress
The Oncological Optimal Tacrolimus Target Level after Liver Transplant for Hepatocellular Carcinoma
K. Sasaki¹, J. McVey¹, D. Firl², Y. Inaba³, C. D. Kwon¹, K. Hashimoto¹, F. Aucejo¹
¹The Cleveland Clinic, Cleveland, OH, ²Duke University, Durham, NC, ³Chiba University, Chiba, Japan
*Purpose: The recurrence rate after liver transplant (LT) for hepatocellular carcinoma (HCC) is high as 15-20% nevertheless of complete removal of tumor and carcinogenic liver.…
2020 American Transplant Congress
Multiple Downstaging Episodes for Hepatocellular Carcinoma Prior to Liver Transplant Increases Risk of Post-Transplant HCC Recurrence
K. Mishra, M. Siddiqui, A. Farris, R. Salgia
Henry Ford Hospital, Detroit, MI
*Purpose: Early-stage Hepatocellular Carcinoma (HCC) is best managed with liver transplantation (LT). Several studies have shown that patients meeting Milan or successfully downstaged to meet…
2020 American Transplant Congress
National Experience with Living Donor Liver Transplant for Hepatocellular Carcinoma
J. Silverstein¹, F. Yao¹, J. D. Grab², H. Braun², J. Roberts², J. Dodge², N. Mehta¹
¹Dept of Medicine, UCSF, San Francisco, CA, ²Dept of Surgery, UCSF, San Francisco, CA
*Purpose: LDLT is an attractive option to decrease both wait time and risk of waitlist dropout in HCC. This study aimed to evaluate temporal and…
2020 American Transplant Congress
HCC Liver Transplantation Waitlist Dropout Rates before and after the Mandated Six-Month Wait-Time
M. LaVere¹, K. Robichaux², J. Buggs³, E. Rogers³, S. Nyce⁴, A. Kumar¹, J. Sokolich³
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁴University of Tampa, Tampa, FL
*Purpose: Studies have shown significant improvement in hepatocellular carcinoma (HCC) recurrence rates following the UNOS implementation of a six-month wait period. However, few have examined…
2020 American Transplant Congress
Comparing Post-Transplant Outcomes in Living and Deceased Donor Liver Transplantation for Patients with Hepatocellular Carcinoma: An Analysis of UNOS Registry
T. Kitajima¹, D. Moonka², S. Yeddula¹, M. Rizzari¹, K. Collins¹, A. Yoshida¹, M. S. Abouljoud¹, S. Nagai¹
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI
*Purpose: Because of possible short waiting time, living donor liver transplantation (LDLT) for HCC may provide survival benefit compared to deceased donor LT (DDLT). This…
2020 American Transplant Congress
Living Donor Liver Transplantation Should Be Considered Cautiously in Recurrent Hepatocellular Carcinoma within the Milan Criteria after Curative Liver Resection
J. Kim¹, N. Yi², G. Choi¹, C. D. Kwon³, K. Lee², K. Suh², J. Joh¹
¹Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, ²Division of HBP Surgery, Department of Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of, ³Department of Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH
*Purpose: Insufficient data are available about patient survival following different treatments for recurrent hepatocellular carcinoma (HCC) after primary hepatectomy. We retrospectively evaluated the effects of…
2020 American Transplant Congress
Hepatocellular Carcinoma Recurrence after Severe Acute Cellular Rejection
M. Najjar¹, O. Perez¹, K. Bruestle¹, A. Qian¹, P. Jiang¹, A. Srivastava¹, Y. Saenger¹, E. Verna¹, E. Zheng¹, A. Mathur¹, A. Griesemer¹, K. Halazun², B. Samstein², T. Kato¹, J. Emond¹
¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: The interplay between acute cellular rejection (ACR), immunosuppression and hepatocellular carcinoma (HCC) recurrence in patients who underwent liver transplantation (LT) for HCC is still…
2020 American Transplant Congress
Synergistic Anticancer Effect of Metformin in Combination with Immunosuppressant on Hepatocellular Carcinoma Cell Lines
S. Suh¹, Y. Choi¹, K. Lee²
¹Surgery, Chung-Ang University, College of Medicine, Seoul, Korea, Republic of, ²Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of
*Purpose: After liver transplantation (LT), immunosuppression is needed to avoid rejection and graft loss, however, it can stimulate hepatocellular carcinoma (HCC) recurrence and progression. Previous…
2020 American Transplant Congress
Outcomes Following Resection of Mixed Hepatocellular-Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma: A Matched Analysis
M. L. Holzner¹, F. Parvin-Nejad², K. Fei³, S. Florman¹, M. E. Schwartz¹, P. Tabrizian¹
¹Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: Mixed hepatocellular-cholangiocarcinoma (HCC-CC) is a biphenotypic liver cancer thought to have unfavorable tumor biology and a poor prognosis. Surgical outcomes of HCC-CC remain unclear.…